Bayer’s (ETR: BAYN) women’s healthcare unit for the South China region is reportedly planning to establish a Shenzhen regional unit, tasked with product promotion in Shenzhen and southern Guangzhou. The move is designed to reinforce Bayer’s prescription drug strategy in China and expand its women’s healthcare segment, according to the German pharmaceutical giant. The decision is based on Bayer’s product pipeline strategy and regional layout considerations.
Organizational Changes
Luo Jiang, the current senior regional manager of the South China women’s healthcare Guangzhou Guangxi great region Guangzhou Group 3, will be promoted to the manager of the Shenzhen great region, reporting to Xiao Lu, director of the South China women’s healthcare division. Additionally, South China women’s healthcare Shenzhen Group 1, Shenzhen Group 2, and Guangzhou Group 4 will join the Shenzhen great region, with relevant managers reporting to Luo Jiang. Li Zhao, senior regional promotion manager of the Guangdong Guangxi great region, will support the business of both regions. Other teams of the Guangdong Guangxi great region will continue to report to Wei Zhiyun, senior regional manager of the Guangdong Guangxi region. All changes will take effect as of November 1, 2022.
Related Business Initiatives
On a related note, Bayer announced in May 2022 plans to set up an oncology business unit in China, effective from June 1, 2022. The unit will be headed by Han Shuang and aims to converge the cardiovascular and diabetes businesses into a metabolic treatment sector.
Future Outlook
The establishment of the Shenzhen regional unit underscores Bayer’s commitment to strengthening its women’s healthcare business in China. By enhancing its regional presence and organizational structure, Bayer aims to improve market penetration and better serve the needs of patients in the South China region.-Fineline Info & Tech
